Abstract
Background: Of all readmissions, 21% are medication-related readmissions (MRRs). However, it is unknown whether MRRs are recognized at the time of readmission and are communicated in the care continuum.
Objectives: To identify the prevalence of MRRs that contain a documentation on the medication involved (and therefore are regarded as recognized), and the proportion of communicated MRRs.
Setting: The study was performed in a teaching hospital.
Methods: In a previous study, a multidisciplinary team of physicians and pharmacists assessed the medication-relatedness, the medication involved and preventability of unplanned readmissions from seven departments. In the current cross-sectional study, two pharmacy team members evaluated the patient records independently. An MRR was regarded as recognized when the medication involved was documented in patient records. An MRR was regarded as communicated to the patient and/or the next healthcare provider when the medication involved or a description was mentioned in discharge letters or discharge prescriptions. The relationship between documented MRRs and whether the MRR was preventable as well as the relationship between (un)documented MRRs and the length of stay (LOS) were assessed. Descriptive data analysis was used.
Results: Of 181 included MRRs, 72 (40%) were deemed preventable by the multidisciplinary team. For 159 of 181 MRRs (88%), a documentation on the medication involved was present. Of 159 documented MRRs, 93 (58%) were communicated to patients and/or caregivers, 137 (86%) to the general practitioner, and 4 (3%) to the community pharmacy. The medication involved was documented less often for potentially preventable MRRs than for non-preventable MRRs (78 vs. 95%; p = 0.002). The LOS was longer for MRRs where the medication involved was undocumented (median 8 vs. 5 days; p = 0.062).
Conclusion: The results of this study imply that MRRs are not always recognized, which could impact patients’ well-being. In this study an increased LOS was observed with unrecognized MRRs. Communication of MRRs to the patients and/or the next healthcare providers should be improved.
Introduction
Unplanned readmissions are an indicator of patient safety. Approximately 20% of patients in the United States experience unplanned readmissions within 30 days after discharge (). These readmissions impact both patients and healthcare providers since they are associated with an increase in morbidity, mortality, health expenditures, and increased workload and stress for healthcare providers (; ; ).
A previous study shows that medication is a major cause of potentially preventable readmissions (). A systematic review reported that 21% of readmissions were medication-related, and 69% of these were potentially preventable (). A recent Dutch study with 1,111 readmissions showed that 16% of readmissions were medication-related, of which 40% were potentially preventable (). Polypharmacy, medication changes during index admission (IA) and hospitalizations before IA could increase the risk of an MRR for elderly patients (). Other studies reported that harm from medicine could significantly increase the length of stay (LOS) (; ; ; ).
To adequately manage medication-related readmissions (MRRs) and minimize extension in the LOS, healthcare providers must recognize the medication involved. In addition, information about the medication involved must be transferred in the care continuum to prevent re-prescription of medication that causes hospitalization. This could contribute to adequate follow-up by primary healthcare providers for patients who for example need help in medication self-management (; ). Patients must also be informed about the impact of their medication use to prevent unintentional re-use of harmful medication (; ).
Previous studies focusing on the recognition of medication-related admissions showed that these were not always recognized by healthcare providers. Non-adherence, prescribing errors (e.g., unintended omission of medication) and certain side effects that overlap with symptoms of co-morbidities were missed (; ; ; ; ; ). Furthermore, a descriptive study showed that of 104 adverse drug reactions patients experienced during hospitalization only 51% were documented in discharge letters for the general practitioner (). However, these previous studies did not focus on the recognition of (potentially preventable) MRRs and their communication to patients and/or the next healthcare providers.
Therefore, the objectives of this study were to: 1) identify the prevalence of documented (and thus recognized) MRRs at the time of readmission, 2) examine the relationship between documented MRRs and whether the MRR was preventable, 3) examine the relationship between documented MRRs and the LOS, and 4) assess the proportion of MRRs that were communicated to patients or caregivers, and/or the next healthcare providers.
Materials and Methods
Study Design and Participants
This cross-sectional single-center observational study was conducted at the OLVG teaching hospital in Amsterdam, the Netherlands. Data were derived from prior research that focused on all causes of readmissions at seven participating departments (; ). Patients were prospectively included if they were readmitted between July 2016 and February 2018. Methodological approval was obtained from the scientific review committee of the hospital (Advies Commissie Wetenschappelijk Onderzoek Medische Ethische Commissie, ACWO-MEC; registration number 16-028). Patient data were acquired and managed as compliant with the privacy regulations.
This study used definitions, inclusion and exclusion criteria similar to that of the prior research (; ). An index admission (IA) was defined as the first admission within the study period of July 2016 and February 2018 where a patient was included. Inclusion criteria were unplanned readmissions within 30 days after discharge from an IA to one of the seven participating clinical departments, namely cardiology, gastroenterology, internal medicine, neurology, psychiatry, pulmonology and general surgery. These departments were selected owing to their readmission rates in previous years in OLVG. Only adult patients (≥18 years) were included. Exclusion criteria were patients transferred to another hospital during IA, patients who left against medical advice during IA, readmissions due to attempted suicide and readmissions unrelated to IA. For the current study, readmissions regarded as non-medication-related were also excluded (see the next paragraph). If a patient had multiple readmissions during the study period, each readmission was assessed separately. This meant that for a second readmission the first readmission was regarded as an IA to assess the causality and preventability of the second readmission in relation to the first readmission.
Usual Care
Medication monitoring was performed by pharmacists using a computerized system to check for the right dose or medication interactions. During the study, transitional care was present at some departments and was implemented further gradually. This included medication reconciliation at hospital admission and discharge. No formal medication review was performed but obvious errors were addressed (e.g., lack of a laxative when an opioid is prescribed or no indication for hypnotics upon discharge). A pharmacy team member explained medication changes to the patient and communicated these to the next healthcare providers. Further details are described in the main study ().
Causality and Preventability Assessments: The Gold Standard
Previous studies have published the methodology for assessing the medication-relatedness and preventability of readmissions more extensively, see Figure 1 for a summary of the different steps (; ). Initially, a research coordinator (medical doctor) screened all readmissions to determine whether they met inclusion criteria. Afterwards, each resident of the seven IA departments and a resident of the hospital pharmacy double-checked the cases to identify possible MRRs. A distinction was made between readmissions caused by medication and readmissions with other causes apart from medication (e.g. diagnostic, management, surgical causes).
FIGURE 1
Questionnaires were used for the assessments (see
Moreover, a senior internist and hospital pharmacist validated all MRRs, as identified at the multidisciplinary meetings. Finally, potentially preventable MRRs were classified into three mutually exclusive subcategories: prescribing errors, transition errors or non-adherence (see Figure 1 for the definitions). This final validation of MRRs was considered the gold standard.
Data Collection and Classification
A research coordinator collected baseline data including patients’ demographics, medical history, IA and readmission characteristics. A resident of the hospital pharmacy and a senior hospital pharmacist visually checked the data on extreme values and missing data (with histograms and scatterplots). Also, as an additional validity check, manually collected data were compared with data extractions from the hospital information system (EPIC Hyperspace, Verona, United States). Differences were discussed, and consensus was met. If consensus could not be met a senior researcher made the final decision.
Data regarding the documentation and communication of medication involved in the readmission were extracted from the hospital information system (see below). Two pharmacy team members evaluated the patient records independently A senior researcher (hospital pharmacist) double-checked all data and consensus was met.
Documentation of Potentially Preventable and Non-Preventable Medication-Related Readmissions
The patient’s readmission records were screened to assess whether and when an MRR was documented and by whom (e.g., clinical notes of physicians, nurses, pharmacists, discharge letters and/or discharge prescriptions). In addition, documentation of the preventability was assessed if applicable. An MRR was regarded as documented—and therefore recognized as medication-related by healthcare providers—when the medication involved was mentioned in the patient records. The record should at least contain the name of the medicine or the medication group (e.g., antihypertensive medication or diabetes medication) as multiple medications could result in a readmission. For preventability, documentation in the patient records should contain the potentially preventable cause for the readmission (e.g., undertreatment, non-adherence, medication error).
MRRs were classified as documented ≤ 24 h of the readmission, > 24 h following readmission or not documented. This last group consisted of readmissions that were classified as MRRs after the causality and preventability assessments of the senior internist and hospital pharmacist (the gold standard).
Communication of Potentially Preventable and Non-preventable Medication-Related Readmissions
The patient records were screened to assess whether MRRs were communicated to patients or caregivers, and/or the next healthcare providers (e.g., general practitioner and community pharmacy). An MRR was regarded as communicated to the general practitioner when the discharge letter specified medication as the cause of the readmission, or when the clinical notes specified a phone call to the general practitioner regarding the MRR. For the community pharmacy, discharge prescriptions were checked to assess whether they contained information on medication-relatedness. Preventability of an MRR was regarded as communicated if specification regarding the potentially preventable cause of the readmission was recorded (e.g., patient non-adherence, medication error). Finally, the patient records were checked to assess whether there was documentation about informing the patient and/or their caregivers regarding the medication-relatedness and potential preventability of their readmission.
Main Outcome Measures
The primary outcome was the prevalence of MRRs that contained documentation on the medication involved in the patient records at the time of readmission. Secondary outcomes were the relationship between documented MRRs and whether the MRR was preventable as well as the relationship between (un)documented MRRs and the LOS. Lastly, the proportion of communicated MRRs to patients or caregivers, and/or the next healthcare providers was assessed.
Data Analysis
All analyses were performed using SPSS version 22.0 (IBM SPSS, Chicago, IL, United States). Categorical variables were presented as percentages. Normally distributed variables were presented as means and standard deviation (SD). Non-normally distributed continuous variables were presented as medians and interquartile range (IQR). Baseline characteristics of potentially preventable and non-preventable MRRs were compared using the independent t-test for continuous variables and the Pearson Chi-square test for frequencies. Descriptive data analysis was used to assess the proportion of readmissions that were documented and communicated. The Pearson Chi-square test was performed to examine the relationship between documented MRRs and whether the MRR was preventable. In addition, the Mann-Whitney U test was performed to examine the relationship between documented MRRs and the LOS. A p-value < 0.05 was considered statistically significant.
Results
A total of 1,356 readmissions ≤30 days after discharge from IA were screened. From this number, 245 were excluded, see Figure 2. Of the remaining 1,111 readmissions (for 873 unique patients), 210 were initially classified as medication-related by residents. After the validation by the senior internist and hospital pharmacist, 181 (16%) readmissions were assessed as MRRs and were included in this study.
FIGURE 2

Patient selection for the current study.
Of these 181 MRRs, 72 (40%) were assessed as potentially preventable, and 109 (60%) were assessed as non-preventable (Figure 2). Prescribing errors (35%) and non-adherence (35%) were the most common causes of potentially preventable MRRs. However, 30% was caused by transition errors. Table 1 shows the baselines and readmission characteristics of the included patients. The mean age of patients with a potentially preventable MRR was 69.5 years (SD 13.7), and that of non-preventable MRRs was 68 years (SD 13.8). Gender was equally represented for potentially preventable and non-preventable MRRs. There were no significant differences between (sub) groups.
TABLE 1
| Characteristicsa | Potentially preventable MRRs (n = 72) | Non-preventable MRRs (n = 109) |
|---|---|---|
| Patient characteristics | ||
| Age, mean (SD) | 69.5 (13.7) | 68 (13.8) |
| Gender, male, n (%) | 38 (52.8) | 63 (57.8) |
| Language barrier present, n (%) | 25 (34.7) | 32 (29.4) |
| Cognitive impairment, n (%) | 26 (36.1) | 21 (19.3) |
| Living situation, n (%) | ||
| • Together with partner/family | 35 (48.6) | 63 (57.8) |
| • Alone | 25 (34.7) | 33 (30.3) |
| • Institution | 10 (13.8) | 13 (11.9) |
| Medical history | ||
| CCI score, median (IQR) | 1 (0–3) | 2 (1–3) |
| eGFR < 50 ml/min/1.73m2, n (%) | 24 (33.3) | 29 (26.6) |
| Previous hospital admission (< 6 months), n (%) | 37 (51.4) | 58 (53.2) |
| Previous ED visit (< 6 months), n (%) | 22 (30.6) | 24 (22.0) |
| IA characteristics | ||
| Unplanned admissions, n (%) | 60 (83.3) | 77 (70.6) |
| Length of stay in days, median (IQR) | 7 (3–13) | 4 (2–10) |
| Departments, n (%) | ||
| • Cardiology | 17 (23.6) | 14 (12.8) |
| • Gastroenterology | 13 (18.0) | 6 (5.5) |
| • Internal medicine | 17 (23.6) | 52 (47.7) |
| • Neurology | 2 (2.8) | 1 (0.9) |
| • Psychiatry | 0 | 1 (0.9) |
| • Pulmonology | 11 (15.3) | 25 (22.9) |
| • General surgery | 12 (16.7) | 10 (9.2) |
| Discharge to home, n (%) | 62 (86.1) | 96 (88.1) |
| Discharge letters sent to GP, n (%) | 61 (84.7) | 92 (84.4) |
| Number of medication at discharge, mean (SD) | 12.6 (5.4) | 10.1 (4.6) |
| Number of medication changes, median (IQR) | 3 (2–6) | 3 (1–5) |
| Readmission characteristics | ||
| Time between IA and readmission in days, median (IQR) | 10.5 (4.3–18.9) | 8 (5–15) |
| Early readmission (≤ 7 days), n (%) | 27 (37.5) | 53 (48.6) |
| Length of stay in days, median (IQR) | 6 (3–11) | 5 (2–7.5) |
| Departments, n (%) | ||
| • Cardiology | 19 (26.4) | 16 (14.7) |
| • Gastroenterology | 10 (13.9) | 9 (8.3) |
| • Internal medicine | 20 (27.8) | 49 (45.0) |
| • Neurology | 4 (5.6) | 2 (1.8) |
| • Psychiatry | 0 | 1 (0.9) |
| • Pulmonology | 9 (12.5) | 22 (20.2) |
| • General surgery | 8 (11.1) | 8 (7.3) |
| • ICU | 2 (2.8) | 2 (1.8) |
Baseline characteristics of potentially preventable and non-preventable medication-related readmissions (MRRs) included in this study.
There were no statistically significant differences between groups. CCI , Charlson Comorbidity index; eGFR , estimated glomerular filtration rate; ED , emergency department; IA = index admission; GP , general practitioner; ICU , intensive care unit.
Documentation of Potentially Preventable and Non-preventable Medication-Related Readmissions
The medication involved was documented in the patient records for 159 of 181 (88%) MRRs, in which 152 (84%) were documented ≤ 24 h of the readmission (see Table 2. The preventability was documented for 51 of 72 (71%) potentially preventable MRRs. The MRRs were often first documented by either a physician (75%) or a nurse (12%).
TABLE 2
| Documentation of MRRs | Total MRRs (n = 181) | Potentially preventable (n = 72) | Non-preventable (n = 109) |
|---|---|---|---|
| Medication-relatedness documented, n (%)a | 159 (87.8) | 56 (77.8)a | 103 (94.5)a |
| • Documented ≤24 h, n (%) | 152 (84.0) | 52 (72.2) | 100 (91.7) |
| • Preventability documented, n (%) | NA | 51 (70.8) | NA |
| • Documented first by | |||
| o physician, n (%) | 136 (75.1) | 51 (70.8) | 85 (78.0) |
| o nurse, n (%) | 22 (12.2) | 4 (5.6) | 18 (16.5) |
| o hospital pharmacist, n (%) | 1 (0.6) | 1 (1.4) | 0 |
Documentation of potentially preventable and non-preventable medication-related readmissions (MRRs) in patient records.
Difference in proportions documented between potentially preventable MRRs, and non-preventable MRRs, was statistically significant (p = 0.002). NA, not applicable.
The medication involved documented for non-preventable MRRs was more than that of the potentially preventable MRRs (95 versus 78%; p = 0.002, see Table 2).
Impact on Length of Stay
Table 3 shows the median LOS for MRRs documenting the medication involved versus MRRs without any documentation. Generally, the median LOS of all undocumented MRRs was longer than that of MRRs that documented the medication involved (median 8 vs. 5 days; p = 0.062). Similar results were found for the subgroups of non-preventable and potentially preventable MRRs.
TABLE 3
| Medication-related readmissions (n = total number; documented) | LOS documented, median in days (IQR) | LOS undocumented, median in days (IQR) | p-value* |
|---|---|---|---|
| All (n = 181;159) | 5 (2–8) | 8 (3.8–12.3) | p = 0.062 |
| Non-preventable (n = 109;103) | 5 (2–7) | 8 (2–9) | p = 0.51 |
| Potentially preventable (n = 72;56) | 5 (2–11) | 8 (4.3–13) | p = 0.12 |
| • Prescribing errors (n = 25; 18) | 4 (1–8.8) | 7 (3–13) | p = 0.42 |
| • Non-adherence (n = 25; 20) | 5 (2–15.3) | 5 (4–11) | p = 0.82 |
| • Transition errors (n = 22; 18) | 6 (3–9) | 13 (11–39.5) | p = 0.010* |
Differences in length of stay (LOS) between potentially preventable and non-preventable medication-related readmissions documented and those not documented during readmission.
Difference in LOS between documented preventable medication-related readmissions, and undocumented preventable medication-related readmissions, caused by transition errors was statistically significant.
The bold values represent the main groups: non-preventable and preventable MRRS.
MRRs caused by transition errors had a significantly longer LOS when the medication involved was undocumented (median 13 days undocumented vs. 6 days documented; p = 0.010).
Communication of Potentially Preventable and Non-preventable Medication-Related Readmissions
Table 4 shows the proportion of MRRs communicated to patients or caregivers, and/or the next healthcare providers. No documentation on the medication involved was recorded for 22 of 181 MRRs (12%). These MRRs were not communicated to patients or caregivers, and/or the next healthcare providers.
TABLE 4
| Communication of documented MRRs | Total documented MRRs (n = 159a) | Documented potentially preventable MRRs (n = 56) | Documented non-preventable MRRs (n = 103) |
|---|---|---|---|
| General practitioner, n (%) | 137 (86.2) | 47 (83.9) | 90 (87.4) |
| • No discharge letter sent, n (%) | 12 (8.8) | 5 (8.9) | 7 (6.8) |
| Community pharmacy, n (%) | 4 (2.5) | 1 (1.8) | 3 (2.9) |
| Patients and/or caregivers, n (%) | 93 (58.5) | 35 (62.5) | 58 (56.3) |
Communication of documented potentially preventable and non-preventable medication-related readmissions (MRRs) to patients or caregivers, and/or the next healthcare providers.
Of 181 MRRs, 159 contained a documentation on the medication involved. For 22 MRRs (12%) there was no documentation on the medication involved resulting in an MRR., For these 22 MRRs, there was also a lack of communication to patients or caregivers, and/or the next healthcare provider(s).
Of 159 MRRs that had documentation on the medication involved, 137 (86%) were communicated to the general practitioner. The information was specified in different sections of the discharge letter, e.g., the anamnesis, the patient evaluation section and/or in the conclusion. Four of 159 MRRs (3%) were communicated to the community pharmacy. For 93 MRRs (58%), information was found in patient records regarding informing the patients and/or their caregivers about the medication-relatedness of the readmission.
Discussion
Our study showed that for 88% of MRRs, the medication involved was documented in the patient records. The medication involved was lacking more often for potentially preventable MRRs than for non-preventable MRRs. An increase in LOS was also found for unrecognized MRRs.
The proportion of recognized MRRs (88%) in this study is higher than those found in previous studies with frequencies of 4.01 and 51.2% (
Our findings showed that 86% of MRRs are communicated to the GP, which is higher than the 51% reported by a previous study (
We found evidence that communication of the medication-relatedness of the readmission was present in 58% of readmissions. A previous study showed that patients’ and healthcare providers’ perspectives on the medication-relatedness of readmissions and their preventability differed (
Study Limitations
A thorough search of the literature reveals that this is the first study to assess the recognition of preventable MRRs and their communication to patients or caregivers, and/or the next healthcare providers. However, some limitations must be considered when interpreting the findings. First, the external generalizability might be limited as this study was performed in a single hospital with a selected number of clinical departments. By including high-risk departments, data assessments efficiency was improved since reviewing data of all readmitted patients is time-intensive. Second, MRRs were assessed by using information from patient records, thus, relevant information from patients and healthcare providers not documented in the patient records could have been missed. For example, communication to patients and/or their caregivers may occur without any documentation. However, we assessed clinical notes that were present from multiple healthcare providers (e.g. nurses, physicians, pharmacists) and not solely discharge letters to minimize the chances of missing any documentation. Third, multidisciplinary meetings might have been held during a patient’s readmission, aiding in the recognition and documentation of MRRs by healthcare providers. This could result in an overestimation of recognized cases. However, the results were expected to be minimally affected as most patients were already discharged when the multidisciplinary evaluations took place. Fourth, this study was exposed to the subjectivity of the researcher who assessed the cases, which could lead to bias. However, a pharmacy team member double-checked the assessments and consensus was met by consulting a senior researcher, which increased the reliability of the results. Finally, this study was underpowered to assess significant differences between study (sub) groups, including LOS, age or type of medication due to the small study population. The results on LOS could be biased and should be interpreted with caution as no adjustments on confounders were performed due to the small number of patients. Further multicenter research with a larger patient population is required to confirm the findings and increase generalizability.
Implications for Clinical Practice
The findings of this study suggest considerable scope for improvements in the clinical healthcare practice and patients’ outcomes. First, cooperation between healthcare providers and patients may improve recognition of MRRs. Uitvlugt et al. showed that patients could offer more medication-related information (e.g., non-adherence) regarding the period after discharge than healthcare providers because this information is often not documented in the patient records (
Conclusion
This study demonstrated that the medication involved was documented in the patient records for 88% of MRRs. The medication involved was lacking more often for potentially preventable MRRs. These findings imply that MRRs are not always recognized, which could impact patients’ well-being. An increased LOS was observed in this study for MRRs that were unrecognized, and a lack of communication in the care continuum was identified. Further multicenter research with a larger patient population is required to confirm the findings of this study.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Ethics statement
The study was approved by the local review board of the hospital (Advies Commissie Wetenschappelijk Onderzoek Medische Ethische Commissie, ACWO-MEC; registration number 16-028). Patient data were obtained and handled in accordance with privacy regulations.
Author contributions
FK-Ç designed the study. ZL and EU collected the data. ZL and FK-Ç analyzed and interpreted the data. ZL, EU and FK-Ç drafted the article.
Acknowledgments
We would like to thank Hanneke Wessemius for help with data collection.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AuerbachA. D.KripalaniS.VasilevskisE. E.SehgalN.LindenauerP. K.MetlayJ. P.et al (2016). Preventability and Causes of Readmissions in a National Cohort of General Medicine Patients. JAMA Intern. Med.176, 484–493. 10.1001/jamainternmed.2015.7863
2
CarterJ.WardC.WexlerD.DonelanK. (2018). The Association between Patient Experience Factors and Likelihood of 30-day Readmission: a Prospective Cohort Study. BMJ Qual. Saf.27, 683–690. 10.1136/bmjqs-2017-007184
3
DaliriS.BekkerC. L.BuurmanB. M.Scholte op ReimerW. J. M.van den BemtB. J. F.Karapinar – ÇarkitF. (2019). Scholte Op Reimer, W. J. M., Van Den Bemt, B. J. F., Karapinar-Çarkit, FBarriers and Facilitators with Medication Use during the Transition from Hospital to home: a Qualitative Study Among Patients. BMC Health Serv. Res.19, 204. 10.1186/s12913-019-4028-y
4
DaviesE. C.GreenC. F.TaylorS.WilliamsonP. R.MottramD. R.PirmohamedM. (2009). Adverse Drug Reactions in Hospital In-Patients: a Prospective Analysis of 3695 Patient-Episodes. PLoS One4, e4439. 10.1371/journal.pone.0004439
5
de LemosJ.LoewenP.NagleC.McKenzieR.YouY. D.DabuA.et al (2021). Preventable Adverse Drug Events Causing Hospitalisation: Identifying Root Causes and Developing a Surveillance and Learning System at an Urban Community Hospital, a Cross-Sectional Observational Study. BMJ Open Qual.10, e001161. 10.1136/bmjoq-2020-001161
6
El MorabetN.UitvlugtE. B.van den BemtB. J. F.van den BemtP. M. L. A.JanssenM. J. A.Karapinar-ÇarkitF.et al (2018). Prevalence and Preventability of Drug-Related Hospital Readmissions: A Systematic Review. J. Am. Geriatr. Soc.66, 602–608. 10.1111/jgs.15244
7
EldenN. M.IsmailA. (2016). The Importance of Medication Errors Reporting in Improving the Quality of Clinical Care Services. Glob. J. Health Sci.8, 54510. 10.5539/gjhs.v8n8p243
8
HohlC. M.RobitailleC.LordV.DankoffJ.ColaconeA.PhamL.et al (2005). Emergency Physician Recognition of Adverse Drug-Related Events in Elder Patients Presenting to an Emergency Department. Acad. Emerg. Med.12, 197–205. 10.1197/j.aem.2004.08.056
9
HuangM.van der BorghtC.LeithausM.FlamaingJ.GoderisG. (2020). Patients' Perceptions of Frequent Hospital Admissions: a Qualitative Interview Study with Older People above 65 Years of Age. BMC Geriatr.20, 332. 10.1186/s12877-020-01748-9
10
JemberA.HailuM.MesseleA.DemekeT.HassenM. (2018). Proportion of Medication Error Reporting and Associated Factors Among Nurses: a Cross Sectional Study. BMC Nurs.17, 9. 10.1186/s12912-018-0280-4
11
JencksS. F.WilliamsM. V.ColemanE. A. (2009). Rehospitalizations Among Patients in the Medicare Fee-For-Service Program. N. Engl. J. Med.360, 1418–1428. 10.1056/NEJMsa0803563
12
MeursE. A. I. M.SiegertC. E. H.UitvlugtE.MorabetN. E.StoffelsR. J.SchölvinckD. W.et al (2021). Clinical Characteristics and Risk Factors of Preventable Hospital Readmissions within 30 Days. Sci. Rep.11, 20172. 10.1038/s41598-021-99250-8
13
MutairA. A.AlhumaidS.ShamsanA.ZaidiA. R. Z.MohainiM. A.Al MutairiA.et al (2021). The Effective Strategies to Avoid Medication Errors and Improving Reporting Systems. Medicines (Basel)8, 46. 10.3390/medicines8090046
14
RiordanC. O.DelaneyT.GrimesT. (2016). Exploring Discharge Prescribing Errors and Their Propagation post-discharge: an Observational Study. Int. J. Clin. Pharm.38, 1172–1181. 10.1007/s11096-016-0349-7
15
RougheadE. E.SempleS. J.RosenfeldE. (2016). The Extent of Medication Errors and Adverse Drug Reactions throughout the Patient Journey in Acute Care in Australia. Int. J. Evid. Based Healthc.14, 113–122. 10.1097/XEB.0000000000000075
16
Sánchez MuñozL. A.Castiella HerreroJ.Sanjuán PortugalF. J.Naya ManchadoJ.Alfaro AlfaroM. J. (2007). Utilidad del CMBD para la detección de acontecimientos adversos por medicamentos[Usefulness of MBDS in detection of adverse drug events]. Med. Interna (Madrid)24, 113–119. 10.4321/s0212-71992007000300003
17
SandovalT.MartínezM.MirandaF.JirónM. (2020). Incident Adverse Drug Reactions and Their Effect on the Length of Hospital Stay in Older Inpatients. Int. J. Clin. Pharm.43, 839–846. 10.1007/s11096-020-01181-3
18
ShawJ. A.StiliannoudakisS.QaiserR.LaymanE.SimaA.AliA. (2020). Thirty-Day Hospital Readmissions: A Predictor of Higher All-Cause Mortality for up to Two Years. Cureus12, e9308. 10.7759/cureus.9308
19
UitvlugtE. B.JanssenM. J. A.SiegertC. E. H.KneepkensE. L.van den BemtB. J. F.van den BemtP. M. L. A.et al (2021). Medication-Related Hospital Readmissions within 30 Days of Discharge: Prevalence, Preventability, Type of Medication Errors and Risk Factors. Front. Pharmacol.12, 567424. 10.3389/fphar.2021.567424
20
UitvlugtE. B.JanssenM. J. A.SiegertC. E. H.LeendersA. J. A.van den BemtB. J. F.van den BemtP. M. L. A.et al (2020). Patients' and Providers' Perspectives on Medication Relatedness and Potential Preventability of Hospital Readmissions within 30 Days of Discharge. Health Expect.23, 212–219. 10.1111/hex.12993
21
UpadhyayS.StephensonA. L.SmithD. G. (2019). Readmission Rates and Their Impact on Hospital Financial Performance: A Study of Washington Hospitals. Inquiry56, 46958019860386. 10.1177/0046958019860386
22
van den BemtP.EgbertsT. (2007). Drug-related Problems: Definitions and Classification. Eur. J. Hosp. Pharm. Pract.13, 62–64.
23
van der DoesA. M. B.KneepkensE. L.UitvlugtE. B.JansenS. L.SchilderL.TokmajiG.et al (2020). Preventability of Unplanned Readmissions within 30 Days of Discharge. A Cross-Sectional, Single-center Study. PLoS ONE15, e0229940. 10.1371/journal.pone.0229940
24
van der LindenC. M.KerskesM. C.BijlA. M.MaasH. A.EgbertsA. C.JansenP. A. (2006). Represcription after Adverse Drug Reaction in the Elderly: a Descriptive Study. Arch. Intern. Med.166, 1666–1667. 10.1001/archinte.166.15.1666
25
Warlé-van HerwaardenM. F.HeringsR. M.EngelkesM.van BlijderveenJ. C.RodenburgE. M.de BieS.et al (2015). Quick Assessment of Drug-Related Admissions over Time (QUADRAT Study). Pharmacoepidemiol. Drug Saf.24, 495–503. 10.1002/pds.3747
26
WitheringtonE. M.PirzadaO. M.AveryA. J. (2008). Communication Gaps and Readmissions to Hospital for Patients Aged 75 Years and Older: Observational Study. Qual. Saf. Health Care17, 71–75. 10.1136/qshc.2006.020842
27
YamC. H.WongE. L.ChanF. W.LeungM. C.WongF. Y.CheungA. W.et al (2010). Avoidable Readmission in Hong Kong--system, Clinician, Patient or Social Factor?BMC Health Serv. Res.10, 311. 10.1186/1472-6963-10-311
Summary
Keywords
hospital readmissions, preventability, medication-related problems, length of stay, quality of heathcare
Citation
Lee Z-Y, Uitvlugt EB and Karapinar-Çarkit F (2022) Medication-Related Readmissions: Documentation of the Medication Involved and Communication in the Care Continuum. Front. Pharmacol. 13:824892. doi: 10.3389/fphar.2022.824892
Received
30 November 2021
Accepted
15 February 2022
Published
21 March 2022
Volume
13 - 2022
Edited by
Jean Paul Deslypere, Aesculape CRO, Belgium
Reviewed by
Chris Gillette, Wake Forest School of Medicine, United States
Lynne Emmerton, Curtin University, Australia
Updates

Check for updates
Copyright
© 2022 Lee, Uitvlugt and Karapinar-Çarkit.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fatma Karapinar-Çarkit, f.karapinar@olvg.nl
This article was submitted to Drugs Outcomes Research and Policies, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.